Indivior Pharmaceuticals, Inc. INDV Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Product | ||||||
| PERSERIS | $5M0.0% | $5M-16.7% | $6M-25.0% | $8M+100% | $4M-55.6% | |
| Sublingual & other | $50M-27.5% | $69M+35.3% | $51M-1.9% | $52M-3.7% | $54M-12.9% | |
| SUBLOCADE | $232M-7.9% | $252M+15.1% | $219M+4.8% | $209M+18.8% | $176M-9.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Indivior Pharmaceuticals, Inc. break its business down?
- Indivior Pharmaceuticals, Inc. (INDV) reports net revenue by product across 3 parts — PERSERIS, Sublingual & other and SUBLOCADE. Each is extracted from the segment footnotes and tracked over time.
- Where does Indivior Pharmaceuticals, Inc. 's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Indivior Pharmaceuticals, Inc. 's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.